Abstract:The causal genes for a large proportion of hereditary colorectal adenomas and early-onset colorectal cancer (CRC) remain to be identified. Here, we identified a germline heterozygous stop-gain mutation p.Arg1953X (rs150312701) of the POLQ (DNA Polymerase Theta) gene, which is co-segregated with disease status, by whole-exome sequencing of twelve hereditary CRC pedigrees. The mutation was validated in an independent pedigree, resulting in ten p.Arg1953X carriers from two CRC families. Mechanically, the heterozygous nonsense mutation led to compensated overexpression of the mRNA with wild-type POLQ allele under DNA damage stress, resulting in hyperactivation of the error-prone theta mediated end-joining (TMEJ) DNA repair pathway, which enables the survival of mutation-enriched cells. Concordantly, tumor tissues from p.Arg1953X mutation carriers showed microsatellite instability and hypermutation, and were resistant to radiotherapy. We found that an FDA-approved antibiotic Novobiocin inhibits the POLQ -mediated TMEJ pathway, eliminates the p.Arg1953X mutation-related resistance to DNA damage, finally benefits tumor radiotherapy. Collectively, we defined a POLQ-mutated CRC type and suggested for a mutation-based potential target therapeutic strategy. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement The study was supported by the National Natural Science Foundation of China and the Applied Basic Research Foundation of Yunnan Province. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All studies were conducted with the approval of the ethics committee of Kunming Medical University (2017-3), and all participants provided written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes

Nonsense suppression induces read‐through of a novel BMPR1A variant in a Chinese family with hereditary colorectal cancer

Identification of a Novel Mutation in the BMPR2 Gene in a Pulmonary Arterial Hypertension Patient Using Next‐generation Sequencing

A C. 1363c > T (P. R455x) Nonsense Mutation Of Rb1 Gene In A Southern Chinese Retinoblastoma Pedigree

A germline heterozygous nonsense mutation causes hereditary colorectal cancer

Germline Mutations in BMPR1A/ALK3 Cause a Subset of Cases of Juvenile Polyposis Syndrome and of Cowden and Bannayan-Riley-Ruvalcaba Syndromes

Germline Variants of CYBA and TRPM4 Predispose to Familial Colorectal Cancer

Integrated systematic functional screen and fine-mapping decipher the role and genetic regulation of RPS19 in colorectal cancer development

A Germline Heterozygous POLQ Nonsense Mutation Causes Hereditary Colorectal Cancer

A Missense Variant in PTPN12 Associated with the Risk of Colorectal Cancer by Modifying Ras/MEK/ERK Signaling

Role of a Rare Variant in APC Gene Promoter 1B Region in Classic Familial Adenomatous Polyposis

A de novo germline mutation of APC for inheritable colon cancer in a Chinese family using multigene next generation sequencing.

Alteration of tumor suppressor BMP5 in sporadic colorectal cancer: a genomic and transcriptomic profiling based study

Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23 by genomewide high-density single nucleotide polymorphism (SNP) scan and identification of BMPR1A loss of function

The Bone Morphogenetic Protein Pathway is Inactivated in the Majority of Sporadic Colorectal Cancers

Targeting translational read-through of premature termination mutations in <i>BMPR2</i> with PTC124 for pulmonary arterial hypertension

Abstract 16991: Rare Variants in BMP10 Confer Risk of Pulmonary Arterial Hypertension

A 16q22.1 Variant Confers Susceptibility to Colorectal Cancer As a Distal Regulator of ZFP90

The orphan nuclear receptor NR0B2 could be a novel susceptibility locus associated with microsatellite‐stable, APC mutation‐negative early‐onset colorectal carcinomas with metabolic manifestation

Clinical and functional characterisation of the SMAD4 germline variant c.1035C > A in a family with juvenile polyposis syndrome by whole-exome sequencing

A novel nonsense mutation in PPP2R5D is associated with neurodevelopmental disorders and shows incomplete penetrance in a Chinese pedigree

Germline Gain‐Of‐Function Mmp11 Variant Results In An Aggressive Form Of Colorectal Cancer